679 results on '"L'Italien, Gilbert"'
Search Results
2. Content Validity of the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) Instrument in Spinocerebellar Ataxia
3. Development and Validation of SCACOMS, a Composite Scale for Assessing Disease Progression and Treatment Effects in Spinocerebellar Ataxia
4. Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying Therapies
5. Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis
6. Early-Life Social Determinants of SCA6 Age at Onset, Severity, and Progression
7. Observational Analysis of the Costs Associated with Acute Treatment of Breakthrough Migraine Attacks in Medicaid Patients Using Preventive Therapies
8. Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)
9. Real-World experience of interictal burden and treatment in migraine: a qualitative interview study
10. Measuring interictal burden among people affected by migraine: a descriptive survey study
11. Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)
12. Development and Validation of SCACOMS, a Composite Scale for Assessing Disease Progression and Treatment Effects in Spinocerebellar Ataxia.
13. Functional Impairments in Patients with KCNQ2-DEE: Associations Among Key Clinical Features (P1-1.007)
14. Re-weighting MDS-UPDRS Part II Items for Optimal Sensitivity to Parkinson’s Disease Progression Using Parkinson’s Progression Markers Initiative Natural History Data (P11-3.012)
15. Matching-adjusted Indirect Comparison of Troriluzole Versus Untreated Natural History Cohort in Spinocerebellar Ataxia (S35.009)
16. Re-weighting MDS-UPDRS Motor Items for Optimal Sensitivity to Parkinson’s Disease Progression in Untreated Patients Using Parkinson’s Progression Markers Initiative Data (S2.004)
17. Development of a Novel Composite Measure (SCACOMS) to Assess Disease Progression in Spinocerebellar Ataxia (P7-3.019)
18. Automated Video-based Characterization of Movement Quality in a Phase III Clinical Trial of Troriluzole in Subjects with Spinocerebellar Ataxia (P6-3.014)
19. Psychometric Validation of the Modified-functional Scale for the Assessment and Rating of Ataxia (P7-3.018)
20. Association of Anti-inflammatory Therapy Use with the Incidence of Parkinson’s Disease: A Person-Time Analysis Among Patients with Autoimmune Diseases (S2.003)
21. Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant
22. Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis.
23. The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature review
24. Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome
25. Correction to: A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States
26. Psychometric Validation of a Modified United Multiple System Atrophy Rating Scale (S43.002)
27. Patient Concept Elicitation Interviews: Insights into Multiple System Atrophy (MSA) Patient Experiences and Relevance of a modified United Multiple System Atrophy Rating Scale (P8-9.003)
28. Real-world Treatment Combinations of Migraine-specific Prescription Medications (P11-12.006)
29. Long-Term Preventive and Acute Treatment of Migraine With Rimegepant Improves Health Related Quality of Life (P12-12.003)
30. Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life
31. Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials
32. Comparison of “Word” vs. “Picture” version of the Free and Cued Selective Reminding Test (FCSRT) in older adults
33. Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)
34. Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
35. A stated preference survey to explore patient preferences for novel preventive migraine treatments
36. The Patient-Related Burden of Pegylated-Interferon-α Therapy and Adverse Events among Patients with Viral Hepatitis C in Japan
37. Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection
38. Projecting Long-Term Graft and Patient Survival after Transplantation
39. A Glycomarker for Short-term Prediction of Hepatocellular Carcinoma: A Longitudinal Study With Serial Measurements
40. Measurement properties of the Flu-Like Symptom Index from the Hepatitis Physical Symptom Severity Diary
41. Value-Based Assessment of Pharmacodiagnostic Testing from Early Stage Development to Real-World Use
42. Hepatitis C viral load, genotype, and increased risk of developing end‐stage renal disease: REVEAL‐HCV study
43. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI
44. The Burden of Illness for Patients with Viral Hepatitis C: Evidence from a National Survey in Japan
45. MSQ Utility Mapping of Rimegepant by Change in Monthly Migraine Days for Preventive Treatment of Migraine (P1-1.Virtual)
46. Acute Treatment with Oral Rimegepant 75 mg Reduces Migraine-Related Disability in Adults With and Without a History of Triptan Treatment Failure: Results from a One-Year, Open-Label Safety Study (P2-2.002)
47. Reduction in Opioid Prescription Fills and Morphine Milligram Equivalent Dispensed Following Initiation of Nurtec ODT Treatment – A Real World Administrative Claims Study (S31.010)
48. Characterizing the natural history of progression in patients with Multiple System Atrophy (P1-1.Virtual)
49. Non-Neurologist Perspectives on Migraine: Results of a cross-sectional advisory board survey (P8-2.001)
50. Reduction in Period Prevalence of Medication Overuse Headache Following Initiation of Nurtec ODT Treatment – A Real World Administrative Claims Study (P12-2.003)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.